GS
Insider
Gary S. Stetz
Interim CEOGary S. Stetz (Interim CEO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in Hepion Pharmaceuticals, Inc. (HEPA). Across 1 priced purchase filing, the average 21-session return was +56.9% from execution and +47.1% from disclosure (delay-adjusted; derived). The largest single filing was $100K of HEPA (2,000,000 sh × $0.05, as filed), executed Aug 3.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+56.9%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+47.1%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells · 1 late
Median delay
9d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$100K
shares × price, as filed
Last traded
Aug 3
Filed Aug 12
Median ADV $1K across their filed names
Open performance→Volume by month
Buys $100K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
HEPARecent filings
HEPAPURCHASE
Hepion Pharmaceuticals, Inc.
View filing →
$100K2,000,000 sh × $0.05
Exec Aug 3
Filed Aug 12 · 9:41 PM ET †